<DOC>
	<DOCNO>NCT01768039</DOCNO>
	<brief_summary>Two hundred forty patient multiple sclerosis meet study criterion enrol randomize double blind placebo-controlled clinical trial . They randomly assign placebo vitamin D treatment group . The total time study 52 week vitamin D group treat weekly 50000 International unit ( IU ) vitamin D , group receive weekly placebo . The annual relapse rate EDSS compare baseline , month 6 12 .</brief_summary>
	<brief_title>Vitamine D Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>BMI:1830kg/m2 caucasian race Relapsing remit multiple sclerosis treatment interferon beta Recent vitamin D supplement therapy Restricted fat diet nephrolithiasis recent 5 year Past history hyperparathyroidism , sarcoidosis , cancer Past history hepatic disease Past history gastrointestinal disease Past history mycobacterial infection Past history hypercalcemia hypercalciuria serum creatinine &gt; 1.5 Smoking , drug abuse corticosteroid therapy recent year treatment thiazide drug inhibit vitamin D absorption Disease attack recent 2 month Serum Ca &gt; 2.6mm0l/L Serum 25 ( OH ) D &gt; 85mmol/L hypersensitivity cholecalciferol Past history heart disease Major depression Uncontrolled hypertension ( BP &gt; 180/110 ) Immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>EDSS</keyword>
	<keyword>ARR</keyword>
</DOC>